Walmart and Johnson & Johnson both reported quarterly results that beat estimates, yet their strategies and valuations point to J&J as the more compelling defensive play. Walmart posted $175.68 billion in Q1 FY27 revenue with U.S. comparable sales up 4.1% and global eCommerce surging 26%, while J&J grew Q1 2026 sales 9.9% driven by an 11.2% jump in Innovative Medicine to $15.43 billion. Walmart trades at a trailing P/E of 40 with a 0.85% yield and saw free cash flow turn negative at -$1.95 billion as capital expenditures rose 34%, whereas J&J sits near a 30 P/E with a 2.01% yield and 21.8% profit margins. J&J also raised full-year adjusted EPS guidance to $11.45 to $11.65 and plans a DePuy Synthes orthopaedics spinoff within 18 to 24 months, while Walmart announced a new $30 billion buyback. With consumer sentiment at 44.8 and prediction markets pricing a 92.5% probability of a J&J Q2 EPS beat, J&J's pipeline, yield, and margins stand out against Walmart's higher multiple and tariff exposure.
Johnson & JohnsonJ&J beat Q1 estimates, raised full-year EPS guidance, and announced a DePuy Synthes spinoff, with strong margins and yield.
Walmart Inc.Walmart's free cash flow turned negative due to rising capex, and its high P/E and tariff exposure are highlighted as concerns despite a buyback.